ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,460.48
      -0.41%
      US Tech 100
      19,181.60
      -0.43%
      Dow Jones
      39,118.86
      -0.12%
      Brent Oil
      84.85
      0.00%
      Bitcoin
      61,607.24
      1.18%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Mainz BioMed NV (MYNZ)

      7. Mainz BioMed NV (MYNZ) News

      MYNZ

      Mainz BioMed NV (MYNZ)

      Mainz BioMed NV
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:MYNZ
      DateTimeSourceHeadlineSymbolCompany
      10/26/20238:01AMGlobeNewswire Inc.Mainz Biomed Appoints Tarrin Khairi-Taraki as VP of Commercial OperationsNASDAQ:MYNZMainz BioMed NV
      10/18/20238:01AMGlobeNewswire Inc.Mainz Biomed Presents Groundbreaking Results of ColoFuture StudyNASDAQ:MYNZMainz BioMed NV
      10/11/20238:01AMGlobeNewswire Inc.Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, DenmarkNASDAQ:MYNZMainz BioMed NV
      10/05/20238:01AMGlobeNewswire Inc.Mainz Biomed to Attend the JonesTrading 2023 Healthcare Summit NASDAQ:MYNZMainz BioMed NV
      10/04/20238:01AMGlobeNewswire Inc.Mainz Biomed Announces Live Launch of ColoAlert® with Bioclinica in RomaniaNASDAQ:MYNZMainz BioMed NV
      09/27/20238:01AMGlobeNewswire Inc.Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on GastroenterologyNASDAQ:MYNZMainz BioMed NV
      09/20/20233:01AMGlobeNewswire Inc.Mainz Biomed to Present at the Cantor Fitzgerald Global Healthcare Conference NASDAQ:MYNZMainz BioMed NV
      09/13/20233:01AMGlobeNewswire Inc.Mainz Biomed’s ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 81%NASDAQ:MYNZMainz BioMed NV
      09/05/20233:01AMGlobeNewswire Inc.Mainz Biomed Announces Strategic Partnership with Ärztliches Labor Dr. Buhlmann, Expanding Footprint in German MarketNASDAQ:MYNZMainz BioMed NV
      08/29/20233:01AMGlobeNewswire Inc.Mainz Biomed to Present at the H.C. Wainwright Global Investment ConferenceNASDAQ:MYNZMainz BioMed NV
      08/22/20233:01AMGlobeNewswire Inc.Mainz Biomed Announces Live Launch of ColoAlert® with testDNA Laboratory in PolandNASDAQ:MYNZMainz BioMed NV
      08/15/20236:23AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MYNZMainz BioMed NV
      08/15/20233:01AMGlobeNewswire Inc.Mainz Biomed Announces Financial Half Year Results 2023 and Provides Corporate UpdateNASDAQ:MYNZMainz BioMed NV
      08/01/20233:01AMGlobeNewswire Inc.Mainz Biomed Announces Live Launch of ColoAlert® with Marylebone Laboratory in the United KingdomNASDAQ:MYNZMainz BioMed NV
      07/18/20233:01AMGlobeNewswire Inc.Mainz Biomed Announces Collaboration with Fugene Genetics in IsraelNASDAQ:MYNZMainz BioMed NV
      07/11/20234:35PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:MYNZMainz BioMed NV
      07/11/20234:15PMEdgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:MYNZMainz BioMed NV
      06/29/20233:01AMGlobeNewswire Inc.Mainz Biomed Secures up to $50M in New FundingNASDAQ:MYNZMainz BioMed NV
      06/28/20234:32PMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:MYNZMainz BioMed NV
      06/28/20234:31PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MYNZMainz BioMed NV
      06/28/20234:31PMEdgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:MYNZMainz BioMed NV
      06/28/20234:30PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:MYNZMainz BioMed NV
      06/28/20233:01AMGlobeNewswire Inc.Mainz Biomed to Attend ESMO World Congress on Gastrointestinal Cancer 2023 in Barcelona, SpainNASDAQ:MYNZMainz BioMed NV
      06/20/20233:01AMGlobeNewswire Inc.Mainz Biomed Expands into Romania Through Partnership with BioclinicaNASDAQ:MYNZMainz BioMed NV
      05/31/20233:01AMGlobeNewswire Inc.Mainz Biomed Expands Commercial Footprint into PolandNASDAQ:MYNZMainz BioMed NV
      05/24/20233:01AMGlobeNewswire Inc.Mainz Biomed Processes First Patients from Colorectal Cancer Screening Campaign Through its Corporate Health Portal in Partnership with Zöeller-KipperNASDAQ:MYNZMainz BioMed NV
      05/16/20236:57AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:MYNZMainz BioMed NV
      05/16/20233:01AMGlobeNewswire Inc.Mainz Biomed Announces First Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:MYNZMainz BioMed NV
      05/10/20233:01AMGlobeNewswire Inc.Mainz Biomed Partners with Microba Life Sciences for the Development of PancAlertNASDAQ:MYNZMainz BioMed NV
      05/03/20233:01AMGlobeNewswire Inc.Mainz Biomed Announces Addition of Eurofins GeLaMed to its Growing Network of Lab PartnersNASDAQ:MYNZMainz BioMed NV
       Showing the most relevant articles for your search:NASDAQ:MYNZ

      Your Recent History

      BIT
      UC2V7Q
      Unicredit Bank
      Delayed Upgrade Clock